Sign in
WithdrawnNo phase

Endocardial Vs Epicardial Ablation for Recurrent Paroxysmal AF

Key facts

Who runs it
University of Rochester
Where
Short Hills, United StatesSee the site
Trial code
Status
Withdrawn
Started
Jan 2025
Expected to end
Jan 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Endocardial PVI
  • Epicardial Posterior Wall Isolation + LAA Exclusion + Endocardial PVI
Record updated
9 November 2023
Why it stopped
Funding issues

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Age > 18 years
  • Symptomatic paroxysmal AF despite prior 1 or 2 PVI procedures within past 10 years (paroxysmal AF lasting up to 7 days before spontaneous termination)
  • Eligible for referral for re-ablation based on current guidelines
  • LA diameter < 6.0 cms on transthoracic echo
  • Willingness to comply with post-procedural follow-up requirements and to sign informed consent

Who cannot take part

  • Prior history of open heart surgery
  • Prior history of pericarditis or pericardiocentesis
  • Prior history of stroke/TIA/systemic embolism
  • Coronary revascularization or valve surgery within 3 months
  • Prior valve surgery using a mechanical prosthesis
  • Women who are pregnant or plan to become pregnant during the course of the trial** Note: Women of childbearing potential must have a negative pregnancy test within 7 days prior to randomization
  • Life expectancy <1 year for any medical condition
  • History of non-compliance to medical therapy
  • NYHA class IV congestive heart failure or LVEF < 25%
  • An estimated glomerular filtration rate (eGFR) < 45mL/min/1.73m2, using the MDRD calculation
  • Inability to undergo AF catheter ablation (e.g., presence of a left atrial thrombus, contraindication to anticoagulation)
  • Persistent or longstanding persistent AF (duration > 1 year)
  • AF due to reversible cause e.g. hyperthyroid state
  • Participation in other clinical trials that will affect the objectives of this study
  • Inability or unwillingness to provide informed consent
  • Resides at such a distance from the enrolling site so travel to follow-up visits would be unusually difficult
  • Does not anticipate residing in the vicinity of the enrolling site for the duration of the trial

Where in United States

  • University of RochesterShort Hills, United States

About the trial

What the trial wants to find out

There is no current accepted and predictably effective ablative therapy for patients with recurrent paroxysmal atrial fibrillation after prior pulmonary vein isolation (PVI). This study will compare redo PVI with hybrid epicardial ablation incorporating posterior wall isolation and LAA clip, and redo PVI.

The 2 groups in the trial

  • Endocardial PVIExisting treatment, for comparison

    Endocardial complete PVI

  • Epicardial Posterior Wall Isolation + LAA Exclusion + Endocardial PVITreatment being tested

    Minimally invasive surgical hybrid ablation using the convergent approach plus LAA exclusion using the clip

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Comparison of Repeat Endocardial PVI Vs Epicardial Posterior Wall Isolation and LAA Clip Plus PVI for Recurrent Atrial Fibrillation After Prior PVI
Record updated
9 November 2023